In Brief: Immunex' Leukine
Executive Summary
Immunex' Leukine: Supplemental PLAs for chemotherapy-induced neutropenia and use in acute myelogenous leukemia will be reviewed by FDA's Biological Response Modifiers Advisory Committee "in early April," Immunex announces March 13. FDA tentatively has set a meeting date for the committee of April 10-11. FDA requested more information on the clinical data submitted for the GM-CSF product sargramostim, the company says; "based on the questions received and discussions with the FDA to date, the company believes these questions and comments can be addressed without posing a significant delay in the review process"...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth